BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 29, 2007
 |  BioCentury  |  Strategy

Amarin takes heart

Amarin Corp. plc has always known that its lead CNS compound, Miraxion, has potential applications in cardiovascular disease. However, the compound's failure in two Phase III trials for Huntington's disease last April led the company to accelerate the timing of its planned move, which would leverage Miraxion's triglyceride-lowering properties and mitigate the risks associated with the company's core CNS focus.

Miraxion is a semi-synthetic, highly purified derivative of the omega III fatty acid (all-cis)-5,8,11,14,17-eicosapen-taenoic acid (ethyl-EPA) that inhibits phospholipase A2. In HD, Miraxion's mechanism of action is believed to involve replenishment of the lipid bilayer, which the company believed would prevent or slow progression from neuronal dysfunction to apoptosis.

Amarin (AMRN; LSE:AMRN, London, U.K.) ran two double-blind, placebo-controlled Phase III studies in which HD patients received either placebo or 2 g of Miraxion twice daily for six months. Neither...

Read the full 688 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >